Advertisement
Australia markets closed
  • ALL ORDS

    8,012.10
    +1.60 (+0.02%)
     
  • AUD/USD

    0.6670
    -0.0003 (-0.05%)
     
  • ASX 200

    7,769.40
    -0.30 (-0.00%)
     
  • OIL

    81.42
    -0.15 (-0.18%)
     
  • GOLD

    2,348.30
    +1.40 (+0.06%)
     
  • Bitcoin AUD

    98,503.73
    +751.12 (+0.77%)
     
  • CMC Crypto 200

    1,366.05
    -16.61 (-1.20%)
     

Corcept Therapeutics (NASDAQ:CORT) stock performs better than its underlying earnings growth over last three years

By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, the Corcept Therapeutics Incorporated (NASDAQ:CORT) share price is up 86% in the last three years, clearly besting the market return of around 55% (not including dividends).

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

Check out our latest analysis for Corcept Therapeutics

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

ADVERTISEMENT

Corcept Therapeutics was able to grow its EPS at 4.5% per year over three years, sending the share price higher. In comparison, the 23% per year gain in the share price outpaces the EPS growth. This suggests that, as the business progressed over the last few years, it gained the confidence of market participants. It's not unusual to see the market 're-rate' a stock, after a few years of growth.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

A Different Perspective

While it's never nice to take a loss, Corcept Therapeutics shareholders can take comfort that their trailing twelve month loss of 9.1% wasn't as bad as the market loss of around 13%. Of course, the long term returns are far more important and the good news is that over five years, the stock has returned 7% for each year. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. If you would like to research Corcept Therapeutics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here